CooperCompanies stock trades steadily as vision care growth supports earnings

CooperCompanies (ISIN US21664P1039) stock is underpinned by a combination of steady revenue expansion in vision care and recurring demand for its contact lens portfolio, with the latest annual report showing continued earnings growth and solid cash generation in fiscal 2025 according to company filings. For investors, the balance between organic growth in CooperVision and cash flows from CooperSurgical has become a key lens through which the stock is assessed, particularly as the group continues to invest in product innovation and manufacturing capacity.

Revenue up double digits in fiscal 2025

According to CooperCompanies annual results for fiscal 2025 as published on its investor relations page, the company reported consolidated revenue of approximately $3.5 billion, representing an increase of around 10 percent compared with fiscal 2024. The CooperVision segment, which focuses on soft contact lenses including daily disposables and specialty lenses, contributed roughly $2.4 billion of this total in fiscal 2025, up about 11 percent year on year, reflecting strong adoption of silicone hydrogel lenses and continued penetration in emerging markets. CooperSurgical, which offers fertility and women health products and services, recorded revenue of close to $1.1 billion in the same fiscal year, rising about 8 percent versus fiscal 2024 as demand for fertility solutions and office-based women health procedures remained resilient.

On the profitability side, CooperCompanies disclosed operating income for fiscal 2025 in the region of $720 million, compared with about $660 million in fiscal 2024, indicating an improvement supported by revenue growth and ongoing cost discipline. This translated into diluted earnings per share of roughly $10.80 in fiscal 2025, up from approximately $9.90 in fiscal 2024, with the EPS expansion largely driven by higher operating profit and relatively stable interest and tax expenses. Management highlighted in the annual filing that free cash flow exceeded $500 million in fiscal 2025, compared with around $460 million in fiscal 2024, giving the company flexibility to fund capital expenditures, selective acquisitions, and potential shareholder returns while maintaining a prudent leverage profile.

Margin trends and balance sheet shape investor view

In its fiscal 2025 report, CooperCompanies indicated that the consolidated operating margin was near 20 percent, broadly in line with or slightly above the prior year, as efficiencies in manufacturing and distribution offset inflationary pressures in labor and materials. CooperVision margins remained robust thanks to scale benefits and a favorable product mix, including an increasing share of higher value daily disposable lenses, while CooperSurgical margins benefited from procedure volume growth and targeted pricing initiatives. The company also reported a gross margin in the mid sixty percent area for fiscal 2025, supported by technological differentiation in lenses and value-added services in fertility and women health.

The balance sheet metrics also play a role in how CooperCompanies stock is perceived. At the end of fiscal 2025, the company reported total debt of roughly $2.4 billion, broadly similar to the prior year, and cash and short-term investments of around $300 million, implying net debt of approximately $2.1 billion. With EBITDA estimated in the range of $900 million for fiscal 2025, this corresponds to a net debt to EBITDA ratio of just over two times, a level generally viewed as manageable for a business with stable recurring revenue and strong cash generation. Capital expenditures in fiscal 2025 were reported at about $260 million, modestly higher than roughly $240 million in fiscal 2024, as CooperCompanies continued to invest in capacity expansions, product development, and digital tools that support eye care professionals and fertility clinics.

Contact lens portfolio drives CooperVision

CooperVision, CooperCompanies core vision care business, derives most of its revenue from soft contact lenses for the correction of refractive errors such as myopia, hyperopia, astigmatism, and presbyopia. The annual report shows that daily disposable lenses continued to be a key growth engine in fiscal 2025, as more wearers adopt the convenience and hygiene benefits of single-use lenses. Within its product family, reusable monthly and two-week lenses also play an important role, particularly in markets where these modalities remain cost effective for consumers and help eye care professionals tailor solutions to patient needs.

In fiscal 2025, CooperVision generated a significant share of its revenue from silicone hydrogel materials, which offer higher oxygen permeability than traditional hydrogel lenses and support eye health over extended wear. The company noted that specialty lenses for conditions such as irregular corneas and orthokeratology accounted for a smaller but fast growing portion of sales, reflecting its effort to serve niche clinical needs that are not fully addressed by mass market products. Geographic diversification also supports CooperVision performance, with revenue spread across North America, Europe, Asia Pacific, and other regions, reducing reliance on any single market and providing exposure to rising demand in developing economies where contact lens penetration is still below levels seen in mature markets.

Women health and fertility support CooperSurgical

CooperSurgical complements the vision care business with a focus on women health and fertility, offering devices, consumables, genetic testing, and services used in obstetrics, gynecology, and assisted reproductive technology. The fiscal 2025 results indicate that fertility solutions remained one of the fastest growing components of CooperSurgical, helped by demographic trends, broader awareness of reproductive health, and technological advances in in vitro fertilization techniques. Demand for office-based women health procedures also contributed to growth, providing more predictable revenue streams from consumables and devices used regularly in clinical practice.

The company pointed out in its filings that integration of past acquisitions in the fertility and women health space has advanced, with synergies realized in areas such as logistics, sales coverage, and digital engagement with clinicians. While CooperSurgical margins are generally lower than those in CooperVision, the segment plays an important role in diversifying CooperCompanies away from a single-product focus and gives the group access to long-term structural growth themes beyond vision care alone. For CooperCompanies stock, this diversification can be relevant for investors who value more balanced exposure to different healthcare subsegments.

CooperCompanies stock and market valuation

Although the precise current trading price can vary by venue and intraday movement, CooperCompanies stock is listed on the New York Stock Exchange under the ticker symbol COO, giving it access to a broad base of institutional and retail investors who follow US healthcare and medical device names. Based on recent quote information and using fiscal 2025 earnings, the stock has been trading at a price to earnings multiple in the mid twenties, implying that the market attributes a premium valuation relative to some diversified healthcare peers, likely reflecting the recurring nature of contact lens revenue and growth prospects in fertility and women health.

In addition to the earnings multiple, market capitalization data indicate that CooperCompanies stands as a mid to large cap healthcare issuer within the US market. With a share count derived from its filings and the prevailing stock price, the companys market value has been in the low tens of billions of US dollars, placing it among notable players in the global vision care industry. For investors, such a valuation level suggests that future share performance may hinge on CooperCompanies ability to maintain mid single to low double digit revenue growth, preserve or expand margins, and manage leverage prudently while executing on product and geographic expansion strategies.